Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09

ConclusionIrinotecan plus panitumumab rechallenge is a promising third-line treatment regimen in patients with metastatic wild-typeKRAS colorectal cancer.Clinical Trial IdentificationUMIN000015916.

Source: Targeted Oncology - October 31, 2021 Category: Cancer & Oncology Source Type: research